Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L)...

Full description

Bibliographic Details
Main Authors: Michael P. Lux, Naiba Nabieva, Andreas D. Hartkopf, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Diethelm Wallwiener, Andreas Schneeweiss, Sara Y. Brucker
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Cancers
Subjects:
advanced breast cancer
metastatic
chemotherapy
antihormone therapy
HER2 c-erbB2
HER2/neu
trastuzumab
pertuzumab
T-DM1
lapatinib
Online Access:http://www.mdpi.com/2072-6694/11/1/10

Internet

http://www.mdpi.com/2072-6694/11/1/10

Similar Items